Abstract
Objective Identify resistance patterns against various antibiotics in Escherichia coli producers and non-producers of extended spectrum beta-lactamases in urinary infections in a population of the Toluca Valley, Mexico
Introduction Escherichia coli is a bacterium that is part of the normal biota of the human being, but under certain conditions it can produce diseases such as gastrointestinal and urinary tract infections for which is the main responsible. Enterobacteriaceae such as Escherichia are extended spectrum betalactamases (ESBL) producers, which makes their treatment difficult due to a high rate of resistance to antibiotics.
Methods 155 samples were collected from patients with suspected urinary tract infection without exclusion criteria such as age or gender. Automated equipment was used for the identification of the etiological agent and sensitivity tests. For the determination of ESBL, the double disc technique was used.
Results 35 strains of Escherichia coli were obtained, of which 45.72 % have ESBL, these strains show 100 % resistance to betalactams, as well as high resistance to quinolones and tetracycline ranging from 70 to 100 %. On the other hand, the resistance shown by non-ESBL producing strains is variable both for betalactams and for other antibiotics.
Conclusion Treatment for urinary tract infections has become increasily difficult due to the high rate of resistance to antibiotics, mainly ESBL-producing strains such as the E coli strains in the present study. Where high rates of resistance to different antibiotics used in clinical practice are shown.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received to carry out this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The following study was approved by the ethical committee of the research division of the Faculty of Medicine UNAM.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Yes
